Shang Rong Medical (002551): Foreign Investment Rating Report (Overseas Institutional Investment Rating C)
Review of Shangrong Medical (002551) Annual report: thanks to business promotion and account recovery, the performance increased by 53% in 2017.
Shangrong Medical (002551) three-quarter report comments: rich orders-on-hand, high annual performance and high growth
Shangrong Medical (002551): long-term strong demand for medical construction, buyer's credit + PPP helps the company's high performance growth.
Shangrong Medical (002551) three-quarter report comments: the third-quarter results are in line with expectations and are expected to improve significantly in the fourth quarter compared with the same period last year.
Shangrong Medical (002551): 11% growth in the first three quarters of 2017 is expected to bottom out for the whole year.
Shangrong Medical (002551) report comments: performance is expected to hit bottom, pick up endogenesis and extension to improve the medical industry chain of the whole platform
Shangrong Medical (002551) report comments: performance growth rebounded medical construction orders continue to be rich
Shangrong Medical (002551) report comments: performance growth is in line with expectations and gradually build a hospital industry chain system.
Shangrong Medical (002551) Annual report and Quarterly report comments: revenue recognition delay delay performance recovery in the first quarter
尚荣医疗(002551)季报点评:2016年结算进度滞后 一季度逐步恢复增长
尚荣医疗(002551)点评:吉美瑞挂牌新三板有助推进骨科业务 提高供应链能力
尚荣医疗(002551)调研简报:在手订单丰富 成长后劲十足
【招商证券】尚荣医疗:在手订单丰富,成长后劲十足
【广证恒生咨询】尚荣医疗点评报告:新增合同订单10.57亿元,医建项目落地加速
【广证恒生咨询】尚荣医疗点评报告:新增合同订单10.57亿元,医建项目落地加速
尚荣医疗(002551):新增合同订单10.57亿元 医建项目落地加速
尚荣医疗(002551)点评报告:兰州卫生项目中标3.69亿元 利好业绩放量
【广证恒生咨询】尚荣医疗点评报告:兰州卫生项目中标3.69亿元,利好业绩放量
尚荣医疗(002551)调研简报:医院PPP项目落地加速 下半年业绩释放可期
No Data
No Data